Mysterious interstellar object caught on camera as scientist says it could be an alien spacecraft
First spotted by on July 1, scientists from around the world have now confirmed that this unexpected visitor has travelled through space from a distant star.
Officially titled 3I/ATLAS, the rare interloper is 12 miles (20km) long and hurtling towards the sun at 135,000 miles per hour.
Now, using a powerful telescope in Hawaii, the European Space Agency (ESA) has captured the first video of 3I/ATLAS as it journeys through space.
The short video shows that the object is extremely bright, which means it is either many times larger than any other interstellar object or has another source of illumination.
Most experts agree that this extra illumination is caused by the fact that 3I/ATLAS is an active comet, producing a glowing 'coma' of ice and gas as it approaches the sun.
However, one Harvard professor claims that the light might not be able to be explained by natural means.
Professor Avi Loeb, a physicist at Harvard University, told MailOnline: 'If it is not a comet, then its large brightness would be a big surprise and potentially signal a non-natural origin, perhaps from artificial light.'
3I/ATLAS was detected as a faint speck of light by NASA's Asteroid Terrestrial-impact Last Alert System (ATLAS) telescope.
Since then, professional and amateur astronomers around the world have scrambled to gather more data.
Scientists quickly combed older data to find observations of the object that had previously been missed, in a process called precovery.
Combining these with hundreds of new observations, scientists were able to officially confirm that 3I/ATLAS is an interstellar object.
Currently 420 million miles (670 million kilometres) away from Earth, 3I/ATLAS's trajectory and incredible speed mean it must be passing through our solar system after being ejected by its own star.
NASA predicts that it will reach its closest point to the sun on October 30, at a distance of 130 million miles (210 million km) - passing just within the orbit of Mars.
Thankfully, the object poses no threat to Earth and will pass harmlessly at around 150 million miles (240 million km) away at its closest point.
This is only the third time that scientists have managed to spot an interstellar object passing through the solar system.
The first interstellar object was Oumuamua in 2017, followed by Borisov in 2019.
When Oumuamua was first detected, certain irregularities in its spin and velocity prompted Professor Loeb and his co-author, Dr Shmuel Bialy, to suggest that it could be alien in origin.
Professor Loeb said: 'Oumuamua exhibited a large non-gravitational acceleration which was anomalous given its lack of evaporation.'
Similarly, Professor Loeb now suggests that 3I/ATLAS could be a similar type of alien craft.
While experts say there is no evidence to support this idea, some researchers say we can't rule out the possibility just yet.
Professor Michael Garrett, Director of Jodrell Bank Centre for Astrophysics said: 'More observations are definitely needed.'
Asked whether the object could be an alien craft, Professor Garret responded: 'Who knows - it could be - that's why it will be important to make as many different measurements as possible to test all hypotheses.
'It's unlikely that it is, but that doesn't mean to say we shouldn't check. We don't know much about these interstellar objects, so we learn more each time we encounter one.'
However, Professor Garret added that there is currently no evidence the object is alien in nature, and it is more likely to be 'an icy body that has escaped from another planetary system and wandered by the solar system by chance'.
Currently, the overwhelming majority of evidence points to the fact that 3I/ATLAS is a comet.
This is because astronomers have spotted a nebulous envelope of gas and dust known as a coma surrounding the object as it is heated by the sun.
Based on these observations, both NASA and ESA are now confident enough to confirm that 3I/ATLAS is an interstellar comet.
Dr Mark Norris, an astronomer from the University Of Central Lancashire, said: 'If there's a coma, it by definition is a comet, because this means that it is outgassing.
'This thing is still quite far from the sun, so you can expect, therefore, as it gets closer, you should get a bigger cloud of material; and that should become clear as we get more observations going forward.'
However, by the time the comet reaches its closest point to the Earth, it will be hidden behind the sun, so astronomers will need to wait until it reemerges in December to catch the best observations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
22 minutes ago
- Daily Mail
Scientists reveal foolproof formula for a lifetime of happiness - and it takes just five minutes to perform
It's often said that happiness is about finding joy in the little things in life - and now scientists appear to have found proof in that. Just five minutes a day performing 'micro-acts of joy' that foster positive emotions is enough to banish stress, boost health, and improve sleep quality, experts found. According to stress expert Dr Elissa Epel, listening to laughter, admiring a flower on a local walk or doing something nice for a friend can measurably improve people's emotional well-being and attitudes toward life. Epel, an expert on stress and ageing who oversaw the new research, said: 'We were quite taken aback by the size of the improvements to people's emotional well-being.' Epel's team at the University of California San Francisco studied almost 18,000 people, mainly from the U.S., UK, and Canada, for the web-based 'Big Joy Project' over a two-year period to 2024. It was the first study to look at whether small, easy-to-do acts that take minimal time could have measurable and lasting effects on people. Participants were asked to perform five-ten minute acts of joy for a week. Prof Epel said the thousands of people who took part in her project matched the positive results achieved by programs that required months of classes, for hours at a time. The study, published in the Journal Of Medical Internet Research, asked participants to perform seven acts over seven days, such as sharing a moment of celebration with someone else, doing something kind for another person, making a gratitude list or watching an awe-inspiring video about nature. Prof Epel said her team picked tasks that were focused on promoting feelings of hope and optimism, wonder and awe, or fun and silliness. Each task took under ten minutes, including answering short questions. Participants were quizzed about their emotional and physical health at the start and end of the week-long project, providing a measure of their emotional well-being, positive emotions, and 'happiness agency', along with their stress and sleep quality. The psychologists explained that emotional well-being includes how satisfied people are with their lives and whether they have purpose and meaning. Happiness agency is how much control they feel they have over their emotions. The team found improvements in all areas, and the benefits increased depending on how fully people participated in the program, meaning those who completed all seven days saw greater benefits than those who only managed two or three. While further research was needed, according to Epel, it's clear that a daily dose of joy could help people in trying times: 'All of this well-being stuff, it's not a luxury. 'We often say that we'll let ourselves be happy once we've reached some point or finished some task. Well, we want to flip that – we need the energy of joy to get through the hard parts. These are really necessary skills.'
The Guardian
3 hours ago
- The Guardian
Weedkiller ingredient widely used in US can damage organs and gut bacteria, research shows
The herbicide ingredient used to replace glyphosate in Roundup and other weedkiller products can kill gut bacteria and damage organs in multiple ways, new research shows. The ingredient, diquat, is widely employed in the US as a weedkiller in vineyards and orchards, and is increasingly sprayed elsewhere as the use of controversial herbicide substances such as glyphosate and paraquat drops in the US. But the new piece of data suggests diquat is more toxic than glyphosate, and the substance is banned over its risks in the UK, EU, China and many other countries. Still, the EPA has resisted calls for a ban, and Roundup formulas with the ingredient hit the shelves last year. 'From a human health perspective, this stuff is quite a bit nastier than glyphosate so we're seeing a regrettable substitution, and the ineffective regulatory structure is allowing it,' said Nathan Donley, science director with the Center For Biological Diversity, which advocates for stricter pesticide regulations but was not involved in the new research. 'Regrettable substitution' is a scientific term used to describe the replacement of a toxic substance in a consumer product with an ingredient that is also toxic. Diquat is also thought to be a neurotoxin, carcinogen and linked to Parkinson's disease. An October analysis of EPA data by the Friends of the Earth non-profit found it is about 200 times more toxic than glyphosate in terms of chronic exposure. Bayer, which makes Roundup, faced nearly 175,000 lawsuits alleging that the product's users were harmed by the product. Bayer, which bought Monsanto in 2018, reformulated Roundup after the International Agency for Research on Cancer classified glyphosate as a possible carcinogen. The new review of scientific literature in part focuses on the multiple ways in which diquat damages organs and gut bacteria, including by reducing the level of proteins that are key pieces of the gut lining. The weakening can allow toxins and pathogens to move from the stomach into the bloodstream, and trigger inflammation in the intestines and throughout the body. Meanwhile, diquat can inhibit the production of beneficial bacteria that maintain the gut lining. Damage to the lining also inhibits the absorption of nutrients and energy metabolism, the authors said. The research further scrutinizes how the substance harms the kidneys, lungs and liver. Diquat 'causes irreversible structural and functional damage to the kidneys' because it can destroy kidney cells' membranes and interfere with cell signals. The effects on the liver are similar, and the ingredient causes the production of proteins that inflame the organ. Meanwhile, it seems to attack the lungs by triggering inflammation that damages the organ's tissue. More broadly, the inflammation caused by diquat may cause multiple organ dysfunction syndrome, a scenario in which organ systems begin to fail. The authors note that many of the studies are on rodents and more research on low, long-term exposure is needed. Bayer did not immediately respond to a request for comment. Despite the risks amid a rise in diquat's use, the EPA is not reviewing the chemical, and even non-profits that push for tighter pesticide regulations have largely focused their attention elsewhere. Donley said that was in part because US pesticide regulations are so weak that advocates are tied up with battles over ingredients like glyphosate, paraquat and chlorpyrifos – substances that are banned elsewhere but still widely used here. Diquat is 'overshadowed' by those ingredients. 'Other countries have banned diquat, but in the US we're still fighting the fights that Europe won 20 years ago,' Donley said. 'It hasn't gotten to the radar of most groups and that really says a lot about the sad and sorry state of pesticides in the US.' Some advocates have accused the EPA of being captured by industry, and Donley said US pesticide laws were so weak that it was difficult for the agency to ban ingredients, even if the will exists. For example, the agency banned chlorpyrifos in 2022, but a court overturned the decision after industry sued. Moreover, the EPA's pesticides office seems to have a philosophy that states that toxic pesticides are a 'necessary evil', Donley said. 'When you approach an issue from that lens there's only so much you will do,' he said.
The Guardian
4 hours ago
- The Guardian
Patients with ultra-rare diseases worry new FDA rules will leave them without treatment
US drug regulators have increasingly signaled a focus on faster approvals and rare diseases, but patients with ultra-rare ailments fear they are falling through the cracks, especially given challenges to conducting clinical trials. One drug, elamipretide, garnered a narrow recommendation from independent advisers for the US Food and Drug Administration (FDA), but the agency rejected the drug's application in May and recommended another potential pathway for approval. Patients and advocates worry about new rules on who may receive the medication during this process, and whether the drug will reach approval before the pharmaceutical company runs out of funding for it. It underscores the challenges of making progress on rare and ultra-rare diseases while also making sure treatments are safe and effective. Hope Filchak is a sassy four-and-a-half-year-old who loves swimming in the lakes and pools near her home in Gainesville, Georgia. She's also deaf and blind, with some functional vision in one eye and hearing with an aid in one ear. Hope was born with an extremely rare mitochondrial condition called MLS syndrome, of which there were only 64 documented cases in the US as of 2018. MLS syndrome, for Hope, causes a potentially life-threatening heart condition called cardiomyopathy, which can make her heart pump blood less efficiently. In February 2024, she started sleeping about 17 hours a day, and her speech began regressing. An echocardiogram revealed that Hope's heart function had dropped about 14 percentage points, into potentially hazardous territory. She then started taking elamipretide, an investigational drug for mitochondrial conditions. 'Pretty soon, honestly, she had a lot more energy,' her mother, Caroline Filchak, said. Most importantly, her heart stabilized. Hope's aunt, Anna Bower, said her niece's 'quality of life dramatically improved' and soon after, she was 'running, dancing, and playing' like any other child her age. First developed in 2004, elamipretide has a long history. Advocates for patients with Barth syndrome – another mitochondrial condition with about 150 known patients – asked Stealth BioTherapeutics to pick up the drug in 2014 and shepherd it through the regulatory process. Stealth submitted its first application to the FDA in 2019, and then it went through four different review divisions at the agency. In an October 2024 meeting of the FDA's cardiovascular and renal drugs advisory committee, patients and physicians spoke about the positive effects of the drug, and the advisers eventually voted 10-6 to recommend it. 'Patients and families saw the [advisory committee's] endorsement as an encouraging sign because the FDA almost always follows its recommendation,' Bower said in June. 'But last month, it didn't.' The FDA rejected the application in May. Internal FDA reviewers noted that the drug had not met its endpoint in phase 2 trials of 12 study participants. 'We don't feel like they looked at a totality of evidence where the patient's voice was heard in the decision,' Caroline Filchak said, who added that it's been difficult to measure the effectiveness of the drug because of how rare the disease is. The FDA did offer a new pathway to approval, Stealth said in a press release. That process takes at least eight months, though it can also take years. Stealth laid off 30% of its staff after the rejection. Advocates such as Filchak are worried the company will not be able to continue pursuing approval. 'If [the FDA] drag their feet like they have throughout this entire process, Stealth is not going to be able to continue operations,' she said. Under the new pathway, the medication is not available for infants. Stealth has said that 35 patients around the world are receiving the medication, and two-thirds of them are very sick infants. In a congressional hearing in late June, the Republican representative Earl L 'Buddy' Carter of Georgia asked Robert F Kennedy Jr, the secretary of the US Department of Health and Human Services, about treatments for rare mitochondrial conditions. Carter mentioned two young constituents with these conditions, including Hope Filchak. The children 'need your help in accessing life-saving medications', Carter said, promising to follow up with Kennedy after the hearing. For now, Hope has a three-month supply of the drug. 'For children like Hope, there are no other options,' Bower said. There are no FDA-approved medications like elamipretide, and there are no similar drugs in late-stage development. Caroline Filchak said that this administration 'does have a stated commitment to accelerating therapies for rare diseases. And it seems like this recent decision by the FDA doesn't align with that commitment.' Marty Makary, the FDA's commissioner, recently announced plans to accelerate approval for select drugs and companies. He has also floated the use of machine learning, often called AI, to review applications quickly. But there are already four ways for the FDA to expedite the review of new medications, and the approval speed is not the sticking point for drugs such as these, Filchak said. Elamipretide is an example of the difficulty of developing drugs for ultra-rare conditions – and for approving them based on clinical evidence, said Holly Fernandez Lynch, bioethicist at the University of Pennsylvania Perelman School of Medicine. 'It's not the poster child of FDA efficiency,' Fernandez Lynch said, noting the long time span and the four different review divisions at FDA. 'But it's also not the poster child of 'Oh my God, we have a drug that works amazingly well, and FDA is standing in the way, and why won't they just use their regulatory flexibility?'' The drug hasn't been approved yet because it hasn't met a pre-specified endpoint, Fernandez Lynch added: 'If the evidence doesn't support approval, if the systematic evidence collection doesn't show benefit, then FDA really can't approve it.' The biotech company is now resubmitting data on knee strength improvement as part of its new application. 'Of course, these patients have a need. Of course, they have an altered tolerance for risk and altered tolerance for uncertainty,' said Fernandez Lynch. 'That's the really devastating part of all of this. And it's really heartbreaking, but it does not mean the FDA should grant approval to a product that hasn't been demonstrated effective, because we really don't know that it works.' Approving a medication without this evidence could lead to issues developing other drugs for the same conditions, Fernandez Lynch said. 'People say, 'Well, what's the big deal? These patients have nothing. Just let them try it.' I get that. If I was that mom, I would do the same thing, right? But the FDA has to make judgments for the population,' she said. For Caroline Filchak, who works for a petroleum delivery company, she plans to continue advocating for her daughter and other affected children – and has even gotten the whole family involved. 'You don't, when you think about having a kid, think that you're going to be doing this, but you do what you've got to do for your kids,' she said, noting that she and her husband, Ben, took their seven-year-old son, Thomas, to the October meeting. 'We call him our baby advocate. Ever since that meeting, every night when he would say his prayers, he would pray that the FDA says 'yes'.'
